Company intelligence / Profile preview

Purodiol Do Brasil

São Paulo, São Paulo, Brazil

Ownership: Private
Development stage: Other

Overview

Purodiol is a Brazilian pharmaceutical company specializing in the development and distribution of high-purity, hemp-derived cannabidiol (CBD) products. The company gained prominence as one of the first to receive authorization from ANVISA for the import and commercialization of pharmaceutical-grade CBD in Brazil. Its flagship product, Purodiol, is a purified CBD isolate (99%+) used primarily for the treatment of refractory epilepsy and other neurological conditions. Purodiol focuses on providing standardized, contaminant-free medicinal cannabis solutions to the Brazilian healthcare market through a robust medical education and distribution network.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Purodiol Do Brasil.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purodiol Do Brasil.

Explore the full profile